Asciminib Hydrochloride

• Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or… Pending
  2025-521126-15-00 Phase II 1 country Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 Phase I/II 7 countries Novartis Pharma AG
• Efficacy of asciminib in chronic phase CML patients with T315l mutations Pending
  2025-523491-23-00 Phase II 1 country Friedrich-Schiller-Universitaet Jena
• Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. Recruiting
  2025-522138-29-00 Phase II 6 countries Novartis Pharma AG
• Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME… Recruiting
  2024-512696-12-00 Phase II 2 countries Fondazione Gimema Franco Mandelli Onlus; Grupo Espanol De Leucemia Mieloide Cron…
• Open-label study of Asciminib for CML-CP or CML-AP patients with T315I mutation who are resistant, intolerant or ineligible to ponatinib Recruiting
  2024-516049-38-00 Phase II 1 country Novartis Pharma S.A.S.
• FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting
  2024-517478-68-01 Phase II 1 country HUS-Yhtymae
• Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia. Recruiting
  2023-508129-28-00 Phase I/II 7 countries Novartis Pharma AG
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 Phase III 14 countries Novartis Pharma AG
• Frontline Asciminib combination in chronic phase CML Ended
  2024-516212-24-00 Phase II 1 country Friedrich-Schiller-Universitaet Jena
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended
  2024-510947-71-00 Phase III 10 countries Novartis Pharma AG
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended
  2023-508838-33-00 Phase III 15 countries Novartis Pharma AG
• Asciminib treatment optimization in ≥ 3rd line CML-CP Ended
  2024-511381-36-00 Phase III 7 countries Novartis Pharma AG
• A study of full treatment-free remission in patients with chronic myeloid leukemia Ended
  2024-516122-66-00 Phase II 1 country Novartis Farma S.p.A.
• Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended
  2024-515040-23-00 Phase II 5 countries Novartis Pharma AG

Showing 1–15 of 15 trials